Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX 株式レポート

時価総額：US$3.3b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Crinetics Pharmaceuticals マネジメント

マネジメント 基準チェック /34

Crinetics Pharmaceuticals'の CEO はR. Struthersで、 Dec2008年に任命され、 の在任期間は 15.5年です。 の年間総報酬は$ 5.75Mで、 10.7%給与と89.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.3%を直接所有しており、その価値は$ 46.30M 。経営陣と取締役会の平均在任期間はそれぞれ2.8年と3.8年です。

主要情報

R. Struthers

最高経営責任者

US$5.7m

報酬総額

CEO給与比率10.7%
CEO在任期間15.5yrs
CEOの所有権1.3%
経営陣の平均在職期間2.8yrs
取締役会の平均在任期間3.8yrs

経営陣の近況

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Recent updates

Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Jun 01
Most Shareholders Will Probably Agree With Crinetics Pharmaceuticals, Inc.'s (NASDAQ:CRNX) CEO Compensation

Crinetics: Earlier Data Release For CAH Treatment Bodes Well For Upcoming Conference Data

May 23

Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)

Feb 29

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Nov 28
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Aug 08
Is Crinetics Pharmaceuticals (NASDAQ:CRNX) In A Good Position To Invest In Growth?

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Dec 31
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Sep 14
Here's Why We're Not Too Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Situation

Crinetics Pharmaceuticals GAAP EPS of -$0.81 misses by $0.15, revenue of $0.44M misses by $0.28M

Aug 12

We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Jun 15
We're Not Very Worried About Crinetics Pharmaceuticals' (NASDAQ:CRNX) Cash Burn Rate

Crinetics: Late-Stage Acromegaly Disease Studies Will Be Major Inflection Point

Jun 13

Crinetics Pharmaceuticals: Endocrinology Focus To Pay Off As Multi-Faceted Pipeline Makes Progress

Apr 24

Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

Jan 19
Crinetics Pharmaceuticals (NASDAQ:CRNX) Is In A Good Position To Deliver On Growth Plans

CEO報酬分析

Crinetics Pharmaceuticals の収益と比較して、R. Struthers の報酬はどのように変化したか？
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$235m

Dec 31 2023US$6mUS$614k

-US$215m

Sep 30 2023n/an/a

-US$199m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$175m

Dec 31 2022US$6mUS$590k

-US$164m

Sep 30 2022n/an/a

-US$150m

Jun 30 2022n/an/a

-US$136m

Mar 31 2022n/an/a

-US$119m

Dec 31 2021US$4mUS$567k

-US$108m

Sep 30 2021n/an/a

-US$98m

Jun 30 2021n/an/a

-US$89m

Mar 31 2021n/an/a

-US$79m

Dec 31 2020US$4mUS$544k

-US$74m

Sep 30 2020n/an/a

-US$67m

Jun 30 2020n/an/a

-US$63m

Mar 31 2020n/an/a

-US$59m

Dec 31 2019US$4mUS$542k

-US$50m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$38m

Mar 31 2019n/an/a

-US$31m

Dec 31 2018US$3mUS$410k

-US$27m

Sep 30 2018n/an/a

-US$21m

Jun 30 2018n/an/a

-US$16m

Mar 31 2018n/an/a

-US$12m

Dec 31 2017US$385kUS$350k

-US$9m

報酬と市場: R.の 総報酬 ($USD 5.75M ) は、 US市場 ($USD 6.80M ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: R.の報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

R. Struthers (61 yo)

15.5yrs

在職期間

US$5,747,994

報酬

Dr. R. Scott Struthers, Ph.D. founded Crinetics Pharmaceuticals, Inc. in November 2008 and serves as its Chief Executive Officer and President since December 2008. He is Chairman at Radionetics Oncology, I...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
R. Struthers
Founder15.5yrsUS$5.75m1.3%
$ 43.1m
Stephen Betz
Founder & Chief Scientific Officer2.7yrsUS$2.50m0.044%
$ 1.5m
Marc J. Wilson
Chief Financial Officer6.4yrsUS$2.51m0.073%
$ 2.4m
Jeff Knight
Chief Operating Officer2.8yrsUS$2.36m0.0063%
$ 210.3k
Alan Krasner
Chief Endocrinologist6yrsUS$2.16m0.017%
$ 549.3k
James Hassard
Chief Commercial Officer2.3yrsUS$1.71m0.0022%
$ 74.2k
Garlan Adams
General Counsel & Corporate Secretary3yrsデータなしデータなし
Adriana Cabre
Chief Human Resources Officer4.1yrsデータなしデータなし
Kevin Capps
Head of Intellectual Propertyno dataデータなしデータなし
Chris Robillard
Chief Business Officer2.3yrsデータなしデータなし
Dana Pizzuti
Chief Medical & Development Officer1.8yrsUS$3.61m0.0018%
$ 59.6k
Robert Cuddihy
Senior Vice President of Medical Affairsless than a yearデータなしデータなし

2.8yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: CRNXの経営陣は 経験豊富 であると考えられます ( 2.8年の平均在職年数)。

取締役

名称ポジション在職期間報酬所有権
R. Struthers
Founder15.6yrsUS$5.75m1.3%
$ 43.1m
Wendell Wierenga
Independent Chairman of the Board8.7yrsUS$375.31k0.13%
$ 4.5m
Matthew Fust
Independent Director6.3yrsUS$348.56k0.024%
$ 782.2k
Camille Bedrosian
Independent Director3.8yrsUS$339.56k0.0076%
$ 253.2k
Rogerio Vivaldi Coelho
Independent Director2.4yrsUS$338.56k0.014%
$ 464.1k
Weston Nichols
Independent Director6.3yrsUS$338.56k0.0076%
$ 253.2k
Stephanie Okey
Independent Director4.9yrsUS$342.31k0.0076%
$ 253.2k
Caren Deardorf
Independent Director2.3yrsUS$330.06k0.0076%
$ 253.2k
Martin Heinrich Reincke
Member of Scientific Advisory Board2.2yrsデータなしデータなし
John Newell-Price
Member of Scientific Advisory Board2.2yrsデータなしデータなし
William Young
Member of Scientific Advisory Board2.2yrsデータなしデータなし

3.8yrs

平均在職期間

61yo

平均年齢

経験豊富なボード: CRNXの 取締役会 は 経験豊富 であると考えられます ( 3.8年の平均在任期間)。